Now showing items 111-116 of 116
Association of a peripheral blood metabolic profile with coronary artery disease and risk of subsequent cardiovascular events.
(Circ Cardiovasc Genet, 2010-04)
BACKGROUND: Molecular tools may provide insight into cardiovascular risk. We assessed whether metabolites discriminate coronary artery disease (CAD) and predict risk of cardiovascular events. METHODS AND RESULTS: We performed ...
Genome-wide association study of Lp-PLA(2) activity and mass in the Framingham Heart Study.
(PLoS Genet, 2010-04-29)
Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) is an emerging risk factor and therapeutic target for cardiovascular disease. The activity and mass of this enzyme are heritable traits, but major genetic determinants ...
Outcomes of Patients with Critical Limb Ischaemia in the EUCLID Trial.
(European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, 2018-01)
OBJECTIVES:Critical limb ischaemia (CLI) implies an increased risk of cardiovascular morbidity and mortality, and the optimal antithrombotic treatment is not established. DESIGN, MATERIALS, METHODS:The EUCLID trial investigated ...
Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trial.
(Vascular medicine (London, England), 2018-12)
Patients with peripheral artery disease (PAD) are at heightened risk of cardiovascular morbidity and mortality. We sought to evaluate the risk of concomitant coronary artery disease (CAD) in patients with symptomatic PAD ...
Pain Phenotypes and Associated Clinical Risk Factors Following Traumatic Amputation: Results from Veterans Integrated Pain Evaluation Research (VIPER).
(Pain medicine (Malden, Mass.), 2016-01)
OBJECTIVE:To define clinical phenotypes of postamputation pain and identify markers of risk for the development of chronic pain. DESIGN:Cross-sectional study of military service members enrolled 3-18 months after traumatic ...
Effect of Once-Weekly Exenatide on Clinical Outcomes According to Baseline Risk in Patients With Type 2 Diabetes Mellitus: Insights From the EXSCEL Trial.
(Journal of the American Heart Association, 2018-10)
Background In the EXSCEL (Exenatide Study of Cardiovascular Event Lowering), exenatide once-weekly resulted in a nonsignificant reduction in major adverse cardiovascular events ( MACEs ) and a nominal 14% reduction in all-cause ...